Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pixium's IRIS II CE Mark Stokes Retinal Implant Rivalry

Executive Summary

Competition in the retinal implant market heats up as Pixium CE marks its second-generation bionic vision system, designed to offer key advantages including higher resolution and explantability.


Related Content

Pixium Vision Won't Lose Sight Of Patient Needs In Drive For AMD Solution
Australian Bionic Eye Developer Sets Sights To Enter Market By 2020
OUS Approvals Analysis: Summer Brings Slowdown In CE Marks
CLINICAL CORNER: Spectranetics’ DCB, Pixium’s Bionic Vision, Endologix EVAS, Biocartis’ Liquid Biopsy
Mainstay Set To Launch ReActiv8 Neurostimulator In Germany
Look Out For New ISO 13485’s Widened Scope And Beefed Up Clauses
Retina Implant Lengthens Headstart In Subretinal Implant Market


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts